Cowa LLC Buys 1,500 Shares of Pfizer Inc. (NYSE:PFE)

Cowa LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 21.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,528 shares of the biopharmaceutical company’s stock after buying an additional 1,500 shares during the quarter. Cowa LLC’s holdings in Pfizer were worth $226,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Swedbank AB boosted its position in Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after purchasing an additional 37,636 shares during the period. McAdam LLC boosted its position in Pfizer by 13.9% during the third quarter. McAdam LLC now owns 21,533 shares of the biopharmaceutical company’s stock worth $623,000 after purchasing an additional 2,628 shares during the period. International Assets Investment Management LLC bought a new position in Pfizer during the third quarter worth about $146,481,000. apricus wealth LLC boosted its position in Pfizer by 4.2% during the third quarter. apricus wealth LLC now owns 104,970 shares of the biopharmaceutical company’s stock worth $3,038,000 after purchasing an additional 4,200 shares during the period. Finally, Rowlandmiller & PARTNERS.ADV boosted its position in Pfizer by 1.1% during the third quarter. Rowlandmiller & PARTNERS.ADV now owns 84,109 shares of the biopharmaceutical company’s stock worth $2,434,000 after purchasing an additional 902 shares during the period. Institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Up 1.6 %

Shares of PFE opened at $26.32 on Friday. The firm’s 50 day simple moving average is $26.30 and its 200 day simple moving average is $27.42. The company has a market capitalization of $149.14 billion, a P/E ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period last year, the firm posted $0.10 earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on PFE. Guggenheim reiterated a “buy” rating and set a $33.00 target price on shares of Pfizer in a research report on Monday, February 10th. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Finally, Citigroup lowered their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.